Table 2 Age-specific prevalence of high-risk HPV and precancer among women living with HIV (WLWH)
Age at screening (years) | No. of women screened in the age group | No. of HPV-positive (% of women screened) (95% CI) | Colposcopy attendance among HPV-positive | Histopathology resultsa (% of women attending colposcopyb) (95% CI) | Yield of the screening effortb (% of total women screened) | ||
|---|---|---|---|---|---|---|---|
CIN2+ | CIN3+ | CIN2+ | CIN3+ | ||||
30–34 | 77 | 35 (45.5%) (34.1–57.2%) | 27 (77.1%) | 1 (3.8%) (0.1–19.6%) | 1 (3.8%) (0.1–19.6%) | 1.3% | 1.3% |
35–39 | 160 | 57 (35.6%) (28.2–43.6%) | 41 (71.9%) | 2 (5.0%) (0.6–16.9%) | 2 (5.0%) (0.6–16.9%) | 1.3% | 1.3% |
40–44 | 134 | 46 (34.3%) (26.3–43.0%) | 40 (87.0%) | 4 (10.0%) (2.8–23.7%) | 3 (7.5%) (1.6–20.4%) | 3.0% | 2.2% |
45–49 | 71 | 41 (57.7%) (45.4–69.4%) | 35 (85.4%) | 4 (11.4%) (3.2–26.7%) | 3 (8.6%) (1.8–23.1%) | 5.6% | 4.2% |
Total | 442 | 179 (40.5%) (35.9–45.2%) | 143 (79.9%) | 11 (7.8%) (4.0–13.5%) | 9 (6.4%) (3.0–11.8%) | 2.5% | 2.0% |